Tipsheet
What matters at India’s listed companies
Earnings · Medical Equipment · Micro cap

Prevest Denpro's FY26 call repeats known numbers; 3D printers shine

Revenue ₹71.81 cr, net profit ₹20.49 cr, both up ~13%. US exports lead. Capacity utilisation on new lines at 18-20% leaves ₹125 cr potential far off.

1 earlier story on Prevest Denpro Ltd.
Mkt cap₹454 cr
P/E22.17×
ROE17.20%
Debt / eq.0.00
162% Surge in Omni brand 3D printer sales since Nov 2024

What's new

  • Revenue ₹71.81 cr, net profit ₹20.49 cr — both up ~13% YoY.
  • 3D printer sales jumped 162%, driving digital dentistry revenue up ~40%.
  • US exports grew 37.58% via Accudent; domestic H2 recovery of 16.19%.
  • Management targets indigenous 3D printer by 2028, four new products in 12 months.

Why this matters

The call confirms a digital dentistry pivot with real traction. But the 18-20% capacity utilisation on new lines means the ₹125 cr revenue potential is a multi-year stretch. No new material disclosure here, just a routine post-earnings chat.

What we're watching

  • Whether capacity utilisation picks up in FY27.
  • Which of the four new dental products gets commercialised first.
  • Progress on the indigenous 3D printer timeline — 2028 is distant.

The full read

Prevest Denpro's FY26 concall added nothing new. Revenue came in at ₹71.81 cr, net profit at ₹20.49 cr, both up about 13%. The standout is the 162% surge in Omni brand 3D printer sales since November 2024, which pulled digital dentistry revenue up 40%. Exports were solid: US grew 37.58%, domestic recovered 16.19% after a weak first half. Capacity is the forward story. New lines are running at just 18-20% utilisation; potential annual revenue from the facility is ₹125 cr. That is a long ramp. The company targets an indigenous 3D printer by 2028 and four new products in 12 months. Nothing here moves the needle. The market already had the numbers.

Questions answered

How did each geography perform in FY26?
Exports rose 17.58% across 92 countries. The US market grew 37.58% via Accudent subsidiary and private label. Domestic revenue recovered in H2 to post 16.19% growth after early headwinds.
What is the capacity utilisation of the new production lines?
Management stated 18-20% utilisation for new lines. The total facility can generate ₹125 crore in annual revenue at full capacity.
What is the timeline for the indigenous 3D printer?
The company plans to launch a fully indigenous 3D printer by 2028. It is also commercialising four new dental products within the next twelve months.
Why did the oral care segment decline?
The OraDoc oral care segment declined 2% due to regulatory and geopolitical disruptions. No further detail was provided on the call.
Mentioned: Omni brand 3D printers · Accudent subsidiary · ₹125 cr facility potential
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Prevest Denpro Ltd.

Pharmaceuticals
₹470 cr
P/E 22.95×

Latest quarter · Mar 2026

Sales₹19 cr
Net profit₹6 cr
Op. margin+36.5%
EPS₹4.85

Strength & growth

Debt / equity0.00×
Current ratio14.38×
  1. 29 Jun 2026 · 3:57 PM IST Prevest Denpro's FY26 call repeats known numbers; 3D printers shine
  2. 4d ago Prevest Denpro's FY26 transcript: nothing new